|
Market Closed -
Swiss Exchange
11:31:22 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 53.10 CHF | +0.19% |
|
+2.51% | -2.93% |
| 08-05 | Swiss Market Index Extends Rally; Sandoz Shares Gain | MT |
| 08-05 | Basilea Pharmaceutica Bags Additional $5 Million Funding for Antibiotic Development | MT |
Company Valuation: Basilea Pharmaceutica AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 484.7 | 545.8 | 422.9 | 501.2 | 672.1 | 658.2 | - | - |
| Change | - | 12.62% | -22.52% | 18.52% | 34.1% | -2.07% | - | - |
| Enterprise Value (EV) 1 | 552.8 | 630 | 473.9 | 472.6 | 585.2 | 509.4 | 447 | 459.3 |
| Change | - | 13.97% | -24.78% | -0.28% | 23.84% | -12.95% | -12.26% | 2.76% |
| P/E | -70.6x | 44.9x | 41x | 7.09x | 17.4x | 13x | 15.6x | 39.2x |
| PBR | - | - | -42.3x | 6.17x | 5.26x | 3.56x | 2.7x | 2.97x |
| PEG | - | -0x | -2.6x | 0x | -0.4x | 0.4x | -1x | -0.7x |
| Capitalization / Revenue | 3.27x | 3.69x | 2.68x | 2.4x | 2.89x | 2.53x | 2.43x | 3.26x |
| EV / Revenue | 3.73x | 4.26x | 3.01x | 2.27x | 2.52x | 1.95x | 1.65x | 2.27x |
| EV / EBITDA | 287x | 32.1x | 22.8x | 7.51x | 11x | 7.87x | 8.88x | 60.7x |
| EV / EBIT | 461x | 34.1x | 24.7x | 7.72x | 11.4x | 7.08x | 9.17x | 63.1x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.58 | 1.02 | 0.86 | 5.83 | 3.14 | 4.073 | 3.406 | 1.354 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 148.1 | 147.8 | 157.6 | 208.5 | 232.4 | 260.6 | 270.5 | 202.2 |
| EBITDA 1 | 1.926 | 19.64 | 20.78 | 62.91 | 53.36 | 64.71 | 50.37 | 7.57 |
| EBIT 1 | 1.2 | 18.5 | 19.2 | 61.2 | 51.5 | 71.93 | 48.73 | 7.279 |
| Net income 1 | -6.8 | 12.15 | 10.5 | 77.6 | 40.2 | 53.56 | 44.43 | 18.54 |
| Net Debt 1 | 68.1 | 84.17 | 50.98 | -28.65 | -86.9 | -148.8 | -211.2 | -198.9 |
| Reference price 2 | 40.92 | 45.80 | 35.30 | 41.35 | 54.70 | 53.10 | 53.10 | 53.10 |
| Nbr of stocks (in thousands) | 11,844 | 11,918 | 11,980 | 12,121 | 12,288 | 12,396 | - | - |
| Announcement Date | 2/15/22 | 2/14/23 | 2/13/24 | 2/18/25 | 2/17/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.04x | 1.95x | 7.87x | -.--% | 811M | |
| 33.04x | 5.91x | 17.56x | 0.97% | 48.42B | |
| -21.14x | 288.75x | -21.43x | -.--% | 43.66B | |
| 45.52x | 5.25x | 28.69x | -.--% | 39.51B | |
| 30.48x | 3.03x | 13.08x | -.--% | 38.95B | |
| 30.58x | 8.82x | 22.17x | 0.38% | 32.61B | |
| 32.9x | 5.38x | 24.45x | -.--% | 16.15B | |
| 23.48x | 2.05x | 8.89x | 1.15% | 14.16B | |
| 74.93x | 3.96x | 15.35x | -.--% | 13.37B | |
| Average | 29.20x | 36.12x | 12.96x | 0.28% | 27.52B | |
| Weighted average by Cap. | 26.39x | 55.23x | 12.17x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BSLN Stock
- Valuation Basilea Pharmaceutica AG
Select your edition
All financial news and data tailored to specific country editions
